Reishi and Cholesterol Management: Triterpene Mechanisms

Mushrooms & Cardiovascular Health

49 animal studies

A 2023 meta-analysis of 49 animal studies found reishi produced large, significant reductions in LDL, total cholesterol, and triglycerides. The systematic review of human randomized trials found no significant benefit.

Journal of Research in Medical Sciences, 2023

SMD -2.03

reduction in LDL-C across animal studies: a large effect size confirmed by the 2023 meta-analysis of G. lucidum research

0

human randomized controlled trials showing significant cholesterol reduction for reishi per the Cochrane-type systematic review (Klupp 2015)

Ganoderic acids

reishi's triterpene compounds that inhibit HMG-CoA reductase in vitro, the same enzyme class targeted by prescription statins

Journal of Research in Medical Sciences, 2023

View as image ↗

The animal research on reishi and cholesterol is genuinely impressive. A 2023 meta-analysis compiled data from 49 animal studies and found that Ganoderma lucidum supplementation produced statistically significant reductions across every major lipid parameter: LDL-cholesterol (standardized mean difference -2.03), total cholesterol (-1.51), triglycerides (-1.52), and VLDL (-1.06), alongside increases in HDL (+1.03).^[1]

Those are large effect sizes. In the animal models, reishi was performing like a meaningful lipid-lowering intervention.

Then there is the human data. A systematic review by Klupp and colleagues that assessed reishi specifically against human randomized controlled trials reached a different conclusion: the evidence does not support the use of G. lucidum for treatment of cardiovascular risk factors in people with type 2 diabetes or hyperlipidemia, with no significant improvement in LDL, total cholesterol, or blood pressure.^[2]

These two bodies of evidence exist simultaneously. Most content about reishi and cholesterol either presents the animal data as definitive or ignores it in favor of the clinical review. This article presents both, explains why they diverge, and covers what reishi might genuinely contribute to cardiovascular health.

For the complete picture of which mushrooms have the strongest cholesterol-lowering evidence in humans, see Mushrooms That Lower Cholesterol: What the Research Shows.

The Animal Evidence: 49 Studies, Impressive Numbers

The 2023 meta-analysis of G. lucidum animal studies published in the Journal of Research in Medical Sciences analyzed 49 studies and found consistent, large-magnitude effects across lipid parameters.^[1]

The effect sizes (standardized mean differences):

• LDL-cholesterol: -2.03
• Total cholesterol: -1.51
• Triglycerides: -1.52
• VLDL: -1.06
• HDL: +1.03

To give context for these effect sizes: a SMD of 1.0 is considered large in the conventions of clinical research. A SMD of -2.03 for LDL represents a very substantial reduction. In animal models, reishi is not showing subtle effects.

What types of animals? Rats and mice, primarily. Animal models of hyperlipidemia can involve dietary induction of high cholesterol. These are not naturalistic models of human cardiovascular disease, and the species-specific metabolic differences between rodents and humans matter for how reliably animal lipid-lowering effects translate.

The mechanism appears plausible. Ganoderic acids, the triterpene class of compounds unique to reishi, inhibit HMG-CoA reductase in vitro. HMG-CoA reductase is the rate-limiting enzyme in cholesterol synthesis and is the target of prescription statin medications. Rahman and colleagues (2018) reviewed this mechanism directly and found that ganoderic acid inhibition of HMG-CoA reductase in cell and animal models is well-documented, alongside complementary antioxidative effects that may protect LDL from oxidative modification.^[4]

The Human Evidence: What Randomized Controlled Trials Actually Found

Klupp and colleagues' systematic review specifically asked whether the animal evidence translates to human trials. The search covered randomized controlled trials of G. lucidum for cardiovascular risk factors.^[2]

The conclusion: no significant improvement in LDL cholesterol, total cholesterol, or blood pressure in the human trial data. The review covered populations with type 2 diabetes and hyperlipidemia, the two groups most likely to benefit from a cholesterol-lowering intervention.

This is a meaningful negative finding. It does not mean reishi has zero cardiovascular effect in humans. It means that for the specific outcome of measurable serum cholesterol reduction, human randomized trials have not confirmed what animal studies predicted.

The Wachtel-Galor pilot study (2012) is instructive about what human reishi trials look like at this stage of research.^[3] This pilot found a trend toward improved antioxidant status and platelet function in participants taking G. lucidum supplementation, without significant serum cholesterol changes. The study was small and limited, but it suggests that if reishi has cardiovascular benefit in humans, it may be through mechanisms other than direct serum lipid reduction.

The broader mushroom evidence reinforces this picture. The 2023 Uffelman systematic review of 22 mushroom studies across multiple species found that mushroom consumption consistently improved serum triglycerides and high-sensitivity CRP, but did NOT significantly affect LDL cholesterol, total cholesterol, HDL, fasting glucose, or blood pressure overall.^[6] Reishi's performance in human trials fits this broader pattern.

The Ganoderic Acid Mechanism: Documented in the Lab, Unconfirmed in the Clinic

Kozarski and colleagues (2018) published a comprehensive review of cholesterol-lowering mechanisms across edible mushrooms, including the specific pathway by which reishi's triterpenes work.^[5]

The mechanism: ganoderic acids inhibit HMG-CoA reductase, the enzyme that converts HMG-CoA to mevalonate in the rate-limiting step of cholesterol biosynthesis. This is the same enzyme that statins like lovastatin and simvastatin inhibit. In vitro, this inhibition is measurable. In animal models, the downstream effect on serum cholesterol is substantial.

The question is why this mechanism does not appear to produce consistent serum cholesterol changes in humans at the doses and formulations tested.

Several factors may explain the animal-human discrepancy:

Bioavailability. Ganoderic acids are large, lipophilic triterpenoid molecules. Their oral bioavailability in humans has not been characterized in the depth needed to know whether meaningful concentrations reach the liver after typical supplement doses. Animal studies often use gavage administration that achieves higher concentrations than typical human supplement use.

Dose. Animal studies frequently test doses that, when scaled to human body weight, would correspond to consuming very large amounts of reishi extract. Typical supplement doses may fall well short of what would be required to achieve meaningful HMG-CoA inhibition in the human liver.

Form. The type of reishi extract matters. Spore oil, fruiting body water extract, and mycelium powder have different ganoderic acid content. Human trials have used varied preparations that are not easily comparable.

Study quality. The human trials reviewed by Klupp 2015 were small and methodologically heterogeneous. Absence of significant effects in small underpowered trials is not the same as proof of no effect.

What Reishi Actually Seems to Help With Cardiovascularly

The negative cholesterol evidence should not obscure what reishi does show in the human data. Wachtel-Galor 2012 found improvements in antioxidant status and platelet function in the pilot trial.^[3] Rahman 2018 specifically highlighted reishi's antioxidative cardioprotective mechanisms as a parallel pathway to the HMG-CoA inhibition story.^[4]

Oxidative modification of LDL is a key step in atherosclerosis: LDL itself is not directly arterial-damaging, but oxidized LDL is taken up by macrophages in the arterial wall, contributing to plaque formation. If reishi's antioxidant compounds reduce LDL oxidation, that could be cardioprotective without appearing as a serum cholesterol change.

Platelet aggregation is another cardiovascular risk factor where some evidence suggests reishi may have effects. Excessive platelet activity contributes to thrombotic events, and some reishi polysaccharide and triterpene compounds have shown antiplatelet activity in laboratory settings.

These are mechanistically plausible pathways that may explain reishi's reputation as a cardiovascular herb in traditional medicine contexts, even if the specific marker of serum LDL shows no consistent change in human trials.

For a focused look at how reishi's triterpenes may affect arterial health downstream, see How Reishi Triterpenes Protect Against Arterial Plaque Buildup. For the broader cardiovascular role of mushroom antioxidants, see Ergothioneine and Cardiovascular Disease: The Mushroom-Exclusive Antioxidant.

Where Reishi Fits in the Mushroom Cholesterol Landscape

Among mushroom species with cholesterol-related evidence, reishi occupies an unusual position: the best-developed preclinical case among all mushrooms studied, but the weakest-confirmed human evidence for cholesterol specifically.

For context on how other mushrooms compare:

• Oyster mushroom has the strongest human clinical evidence for cholesterol outcomes, with a systematic review finding 8 trials showing improvement in lipid parameters. Its mechanisms include lovastatin (natural HMG-CoA inhibitor) and beta-glucan bile acid sequestration.
• Shiitake has a unique compound (eritadenine) with a distinct mechanism and one double-blind RCT confirming triglyceride reductions.
• Reishi has compelling animal data and documented in vitro mechanisms, but human trials have not confirmed serum cholesterol benefit.

This ranking by evidence strength is what every competitor misses by treating all mushrooms as equivalent. The Kozarski 2018 mechanisms review makes clear that these mushrooms use different pathways, and those pathways translate differently in human trials.^[5]

For the species comparison in full depth, see Oyster Mushroom and LDL Cholesterol: Clinical Evidence and Shiitake and Maitake for High Cholesterol: Head-to-Head Research Comparison. And for vascular health approaches that complement this picture, see Cordyceps and Vascular Health: Endothelial Function and Nitric Oxide.

The Bottom Line

Reishi contains ganoderic acid triterpenes that inhibit HMG-CoA reductase in vitro and produce large, consistent lipid-lowering effects in animal models (49-study meta-analysis: LDL SMD -2.03). Human randomized controlled trials have not confirmed these effects: a systematic review found no significant improvement in LDL, total cholesterol, or blood pressure. The pilot human evidence suggests reishi may have more consistent effects on antioxidant status and platelet function than on serum cholesterol directly. The animal-human discrepancy likely reflects bioavailability limitations, dose differences, and formulation heterogeneity between preclinical and clinical research.

Frequently Asked Questions

Does reishi mushroom lower cholesterol?

Animal studies show large cholesterol reductions from reishi supplementation (a 2023 meta-analysis of 49 studies found LDL reductions with SMD -2.03). However, a systematic review of human randomized controlled trials found no significant benefit for cholesterol, total cholesterol, or blood pressure in people with hyperlipidemia or type 2 diabetes (Klupp et al., 2015). The animal evidence is strong; the human evidence does not support it yet.

What do ganoderic acid triterpenes do for cholesterol?

Ganoderic acids in reishi inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis and the target of prescription statin medications. This inhibition is measurable in cell studies and produces substantial cholesterol reductions in animal models. Whether this mechanism produces meaningful effects at typical supplement doses in humans has not been confirmed by randomized clinical trials (Rahman et al., 2018).

Is reishi good for heart health?

The pilot human data suggests reishi may improve antioxidant status and platelet function, which are cardiovascular-relevant outcomes distinct from serum cholesterol (Wachtel-Galor et al., 2012). Whether these effects translate to meaningful cardiovascular risk reduction is not established by available clinical trial evidence. The cholesterol-specific human evidence is negative.

Can reishi replace statins for high cholesterol?

No. Prescription statins have extensive randomized clinical trial evidence demonstrating cholesterol reduction and cardiovascular event prevention. Reishi has not shown significant cholesterol lowering in human randomized trials. The mechanism is related (HMG-CoA reductase inhibition), but the human clinical evidence for reishi is not comparable to the statin evidence base.

What does the research say about reishi and cholesterol?

The research tells two different stories. Animal studies (49 studies in a 2023 meta-analysis) consistently show large cholesterol reductions. Human randomized controlled trial systematic reviews (Klupp 2015) find no significant effect on LDL, total cholesterol, or blood pressure. The overall 22-study mushroom systematic review (Uffelman 2023) found mushrooms consistently improve triglycerides but not LDL, a pattern that fits the reishi human data.

How long does it take for reishi to lower cholesterol?

Human clinical trials of reishi have not established a timeline for cholesterol reduction because those trials have not confirmed significant cholesterol reduction in the first place (Klupp 2015). Animal studies show effects within weeks, but these findings have not been replicated in human trials. The question of how long it takes is not yet answerable from the published clinical evidence.

Sources & References

1. 1. Source details for this reference are not yet available.
2. 2. Source details for this reference are not yet available.
3. 3. Source details for this reference are not yet available.
4. 4. Source details for this reference are not yet available.
5. 5. Source details for this reference are not yet available.
6. 6. Source details for this reference are not yet available.